

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版年	出版名	ページ
北川智余恵，中畑征史， <u>坂 英雄</u> .	3.神経毒性		オンコロジークリニカルガイド肺癌化学療法	南山堂	東京	2014年	380-4
北川智余恵，伊勢裕子， <u>坂 英雄</u> .	IV 基礎研究 副作用予測のためのバイオマーカー.		抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-	日本臨床	東京	2015年	114-9

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yuki Misumi, <u>Makoto Nishio,</u> <u>Toshiaki Takahashi,</u> Fumiyoshi Ohyanagi, Atsushi Horiike, Haruyasu Murakami, Hirotsugu Kenmotsu, <u>Nobuyuki</u> <u>Yamamoto,</u> Mari Ishii, Tsuneo	A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer	Japanese Journal of Clinical Oncology	44(2)	116-121	2014

<p>Shimokawa, Naoya Hida, Hiroaki Okamoto</p>					
<p>Takaaki Tokito, Hirotsugu Kenmotsu, Reiko Watanabe, Ichiro Ito, Takehito Shukuya, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Tateaki Naito, Haruyasu Murakami, <u>Toshiaki</u> <u>Takahashi</u>, Yasuhisa Ohde, Haruhiko Kondo, Masahiro Endo, Toru Kameya, Takashi Nakajima,</p>	<p>Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens</p>	<p>International Journal of Clinical Oncology</p>	<p>19(1)</p>	<p>63-67</p>	<p>2014</p>

Keita Mori, <u>Nobuyuki Yamamoto</u>					
Kazushige Wakuda, Hirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, Mitsuhiro Isaka, Shoji Takahashi, Akira Ono, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Keita Mori, Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde, <u>Toshiaki</u>	Molecular profiling of small cell lung cancer in a Japanese cohort	Lung Cancer	84(2)	139-144	2014

<u>Takahashi,</u> <u>Nobuyuki</u> <u>Yamamoto</u>					
Hisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, <u>Hiroaki Akamatsu,</u> Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, <u>Nobuyuki</u> <u>Yamamoto, Toshiaki</u> <u>Takahashi</u>	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer	Annals of Thoracic Medicine	10(1)	61-66	2015

<u>Seto T, Takahashi T,</u> <u>Yamanaka T,</u> <u>Harada H, Nokihara</u> <u>H, Saka H, Nishio</u> <u>M, Nakagawa K,</u> <u>Takayama K,</u> <u>Ishimoto O, Takeda</u> <u>K, Yoshioka H,</u> <u>Tachihara M, Sakai</u> <u>H, Goto K,</u> <u>Yamamoto N</u>	Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial	J Clin Oncol	32:5s	(suppl; abstr 7503)	2014
Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, <u>Seto</u> <u>T, Ichinose Y</u>	Role of surgical resection for patients with limited disease-small cell lung cancer	Lung Cancer	88(1)	52-56	2015

<p>Naito T, <u>Seto T</u>, <u>Takeda K</u>, <u>Goto K</u>, Okamoto I, Nakagawa K, Ohba T, Murakami H, <u>Takahashi T</u>, <u>Yamanaka T</u>, <u>Yamamoto N</u>.</p>	<p>Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.</p>	<p>Lung Cancer</p>	<p>Elsevier</p>	<p>339-343</p>	<p>2014</p>
<p><u>Seto T</u>, Kato T, <u>Nishio M</u>, <u>Goto K</u>, Atagi S, Hosomi Y, <u>Yamamoto N</u>, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, <u>Yamanaka T</u>, Tajima K, Harada R, Fukuoka M, <u>Yamamoto N</u>.</p>	<p>Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.</p>	<p>The Lancet Oncology</p>	<p>Elsevier</p>	<p>1236-1244</p>	<p>2014</p>

<p>Murakami H, <u>Yamanaka T</u>, <u>Seto T</u>, Sugio K, Okamoto I, <u>Sawa T</u>, Hirashima T, <u>Takeda K</u>, Atagi S, Fukuoka M, Nakanishi Y, Nakagawa K, <u>Yamamoto N</u>.</p>	<p>A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non-small-cell Lung Cancer: West Japan Oncology Group.</p>	<p>cancer Science</p>	<p>Wiley</p>	<p>989-995</p>	<p>2014</p>
<p>Wakuda K, Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi S, Ono A, Taira T, Naito T, Murakami H, Mori K, Endo M, Nakajima T, Ohde Y, <u>Takahashi T</u>, <u>Yamamoto N</u>.</p>	<p>Molecular profiling of small cell lung cancer in a Japanese cohort.</p>	<p>Lung Cancer.</p>	<p>84(2)</p>	<p>139-144</p>	<p>2014</p>

Watanabe M, Serizawa M, Sawada T, <u>Takeda K</u> , <u>Takahashi T</u> , <u>Yamamoto N</u> , Koizumi F, Koh Y.	A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood.	J Transl Med.	12	doi:10.1186/1479-5876-12-143(open access)	2014
Wakuda K, Kenmotsu H, Naito T, <u>Akamatsu H</u> , Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, <u>Takahashi T</u> , Endo M, Nakajima T, <u>Yamamoto N</u> .	Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.	Am J Clin Oncol	38(1)	28-32	2015
Imai H, Mori K, Wakuda K, Ono A, <u>Akamatsu H</u> , Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.	Ann Thorac Med	10(1)	61-66	2015

M, Nakajima T, <u>Yamamoto N</u> , <u>Takahashi T</u> .					
Oki M, Yatabe Y, <u>Saka H</u> , Kitagawa C, Kogure Y, Ichihara S, Moritani S.	Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.	Respiration.	89(3)	235-42	2015
Abe T, Takada K, Ohe Y, Kudoh S, Ichinose Y, Ikamoto H, <u>Yamamoto N</u> , <u>Yoshioka H</u> , Minato K, <u>Sawa T</u> , Iwamoto Y, <u>Saka H</u> , Mizusawa J, Shibata T,	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup	J Clin Oncol.	33(6)	575-81	2015

<p>Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T.</p>	<p>Trial JCOG0803/WJOG4307L.</p>				
<p>Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, <u>Saka H</u>, Okamoto H, <u>Takayama K</u>, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, <u>Yamamoto N</u>, Nukiwa T, Nakanishi Y.</p>	<p>Current status and future perspectives of cooperative study groups for lung cancer in japan.</p>	<p>Respiratory Investigation.</p>	<p>52(6)</p>	<p>339-47</p>	<p>2014</p>

<p>Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, <u>Saka H</u>.</p>	<p>Randomized phase III trial of erlotinib versus docetaxel as second - or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA).</p>	<p>J Clin Oncol</p>	<p>32(18)</p>	<p>Aug-02</p>	<p>2014</p>
<p>Mizugaki H, Fujiwara Y, <u>Yamamoto N</u>, Yagishita S, Kitazono S, Tanaka A, Horinouchi H, Kanda S, <u>Nokihara H</u>, Tsuta K, Asamura H, Tamura T</p>	<p>Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases</p>	<p>Jpn J Clin Oncol</p>	<p>44(9)</p>	<p>835-840</p>	<p>2014</p>

<p>Yokouchi H, Kanazawa K, Ishida T, <u>Oizumi S</u>, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.</p>	<p>Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.</p>	<p>Mol Clin Oncol.</p>	<p>2(5)</p>	<p>744-750</p>	<p>2014</p>
<p>Kawashima Y, <u>Inoue</u> <u>A</u>, Sugawara S, <u>Oizumi S</u>, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.</p>	<p>Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.</p>	<p>Respir Investig.</p>	<p>52(3)</p>	<p>190-4</p>	<p>2014</p>

<p>Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, <u>Harada T</u>, Harada M, Takamura K, <u>Oizumi S</u>, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M.</p>	<p>Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer, and Correlation Between the Efficacy/Toxicity and Genetic Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.</p>	<p>Cancer Chemother Pharmacol</p>	<p>74(6)</p>	<p>1149-57</p>	<p>2014</p>
<p><u>赤松弘朗</u>, <u>山本信之</u></p>	<p>小細胞肺癌に対する予防的全脳照射</p>	<p>腫瘍内科</p>	<p>13(1)</p>	<p>91-95</p>	<p>2014</p>
<p><u>赤松弘朗</u>, <u>山本信之</u></p>	<p>Learn more from previous clinical trial. Clinical Traials. Gov number: NCT00016211</p>	<p>PCI 試験今昔 . がん分子標的 治</p>	<p>12(3)</p>	<p>101-102</p>	<p>2014</p>

発表

<u>Seto T, Takahashi T,</u> <u>Yamanaka T,</u> <u>Harada H, Nokihara</u> <u>H, Saka H, Nishio</u> <u>M, Nakagawa K,</u> <u>Takayama K,</u> <u>Ishimoto O, Takeda</u> <u>K, Yoshioka H,</u> <u>Tachihara M, Sakai</u> <u>H, Goto K,</u> <u>Yamamoto N</u>	Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial	J Clin Oncol	32:5s	(suppl; abstr 7503)	2014
--	--	--------------	-------	---------------------	------